Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Advanced Non-Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Yasir Y Elamin, MD) · yyelamin@mdanderson.org · 713-792-3428
Contact: Principal Investigator (Yasir Y Elamin, MD)

Study leads

Yasir Y Elamin, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Biliary Tract Cancer · Breast Cancer · Cervical Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Denver, United States · Miami, United States

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

NSCLC (Advanced Non-small Cell Lung Cancer) · EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Adenocarcinoma of Lung · Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Phoenix, United States · Brainerd, United States

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Cancer · Tumor, Solid · Malignant Neoplasm

Abroad (travel likely)RecruitingPHASE1, PHASE2

Austin, United States · Irving, United States